tTIS Targeted of the Striatum as an Intervention for MUD Patients (NCT07479771) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
tTIS Targeted of the Striatum as an Intervention for MUD Patients
China60 participantsStarted 2026-03-26
Plain-language summary
Targeted temporal interference stimulation (tTIS) of the caudate nucleus can modulate the abnormal electrophysiological activity in individuals with methamphetamine use disorder (MUD), thereby improving their impaired reward-learning behaviors and reducing drug craving.
Who can participate
Age range18 Years – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Individuals aged between 18 and 55 years, irrespective of gender, having completed a minimum of 9 years of education and capable of effectively cooperating in questionnaire evaluations.
* Meet the diagnostic criteria set forth by the DSM-V concerning the amphetamine-type substance addiction.
* A history of utilizing amphetamine-type substances for a duration not less than one year, with a frequency of use being at least once per week.
* Consent to actively cooperate in the completion of subsequent follow-up assessments.
Exclusion Criteria:
* Severe cognitive functional impairments manifested through a history of head trauma, cerebrovascular diseases, epilepsy, etc., or usage of cognitive enhancement drugs in the past 6 months; an intellectual disability with an IQ score less than 70.
* A diagnosis of schizophrenia or other severe mental illnesses as per the DSM-5 criteria.
* Abuse or dependence on other psychoactive substances (excluding nicotine) within the past 5 years.
* Severe organic diseases that might compromise study participation.
* Contraindications to cTBS, such as a history of epileptic seizures or the presence of metallic implants in proximity to the head.
What they're measuring
1
Change of Craving
Timeframe: baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment